clinical trial · NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Eli Lilly and Company·phase3·recruiting·n = 7,140
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseOrforglipronPlacebo
brief summary
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
started
Dec 1, 2025
primary completion
Aug 1, 2031
completion
Aug 1, 2031
last updated
Apr 17, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol